Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

13.18USD
1:30am IST
Change (% chg)

$-0.57 (-4.15%)
Prev Close
$13.75
Open
$13.74
Day's High
$13.75
Day's Low
$13.13
Volume
115,828
Avg. Vol
135,956
52-wk High
$48.74
52-wk Low
$13.13

Select another date:

Wed, May 9 2018

BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63

* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics

* CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES

BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study

* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Five Prime Therapeutics Announces Executive Change

* ‍BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Five Prime Reports Q4 Loss Per Share $1.04

* FIVE PRIME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Select another date: